Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 33,000 people in 75 countries, and markets its products in 190 countries. For more than a decade, Novo Nordisk has pursued a Triple Bottom Line business philosophy, ensuring it balances social and environmental concerns with financial performance.
Novo Nordisk has played a role in improving the lives of people with diabetes in China for nearly 50 years. Today, Novo Nordisk employs more than 3,200 people in China and has trained more than 400,000 Chinese healthcare professionals in diabetes treatment and prevention. In 1997, Novo Nordisk was the first international pharmaceutical company to establish a Research and Development centre in China. In 2012, Novo Nordisk will inaugurate a new state-of-the-art R&D facility with 150 staff, resulting in an additional investment of USD 100 million. Novo Nordisk is also expanding its Tianjin manufacturing facilities with an investment of USD 400 million. Novo Nordisk in China engages in a number of important research and management partnerships and raises public awareness through collaboration with stakeholders and its Changing Diabetes® initiative.